Help Us Try to Create a Measure of Immunity Against Omicron!

Brevitest announces the launch of our first Omicron clinical trial!

Starting Friday, January 7, 2022, Brevitest will be conducting a clinical trial with our customers to study antibody response to Omicron and other SARS-CoV-2 variants.

Here’s how it works:

  1. When you purchase a Quantimmune™ COVID-19 IgG Antibody Test from us, you will be enrolled in our Omicron clinical trial. (If you don’t want to participate,, no problem; it’s easy to opt-out on the standard Patient Information Form you fill out prior to your test.)
  2. When we take your fingerstick sample at our CLIA-certified laboratory, we will run a Quantimmune™ COVID-19 IgG WS Antibody Test as we normally do, and report the results to you via email, usually within 15 minutes. We always collect about 10µl of fingerstick blood (one drop) for your test, and that gives us some extra in case your test fails one of our internal quality control checks. However, this rarely happens so we generally have extra sample that we safely dispose of after your test is complete.
  3. Once we have successfully run your test, we will use your extra sample to run a Quantimmune COVID-19 IgG OV CT-001 Antibody Test, the clinical trial version of the test we are developing to measure your antibody response against the Omicron variant. (If there is still sample left over after that, we may also use it to test against other variants to help improve our understanding of how antibodies interact with multiple variants.)​
That’s it - pretty simple. NO ADDITIONAL BLOOD SAMPLE IS REQUIRED. All we need is for you to give us permission to use your extra sample for our clinical trial.
Once we’ve collected and run enough samples, we plan to analyze the data and see if we can develop a way to assess your antibody response to the Omicron variant. Of course, there is no guarantee that we can figure this out (that’s why they call it research!), but we are hopeful that our experience with hundreds of patient samples and our team’s extensive knowledge of COVID-19 antibodies will allow us to find a way.
If we are able to come up with a good analytical model, we will publish the results. Moreover, if we are able to apply that model to your individual test results, we will notify you via email and give you access to your results.

We hope you will work with us on this exciting clinical trial.

We expect that it will take somewhere between 100 and 250 samples to gather enough data for our analysis, so please share this opportunity with your family and friends!

To join the effort, just click the Book Now button below and schedule an appointment at a convenient time.

Test* Before You Boost

Quantimmune

The Fast, Easy, Accurate, Quantitative
Immune Response Monitoring System That
Only Uses a Fingerstick Sample of Blood

*This test was developed and its performance characteristics determined by Brevitest Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Always consult with your physician or other health care professional before taking any actions based upon information provided in this video.

Why Brevitest?

Fast, Easy, Accurate

One drop (10µl) of your blood from a fingerstick and 15 minutes later our CLIA lab's cloud-based system produces personalized test results for you and your doctor's review.

International Standard

Brevitest’s COVID-19 IgG point-of-care antibody test measures antibody concentration using the only IgG standard approved by the World Health Organization (NIBSC 20/136)

Actionable Information

We give you reliable data to answer critical questions about COVID-19, such as the best time to get a booster. We help make important decisions informed decisions.

Recent Posts

What About Omicron?

There is still a lot to learn about the latest SARS-CoV-2 variant of interest, Omicron, but we wanted to share our thoughts.

The Quantimmune™ COVID-19 IgG Antibody Test was developed against the original strain of the SARS-CoV-2 virus, and because Omicron’s emergence is so recent, we have not validated our test against it. However, based upon what we know right today, we expect COVID-19 antibodies to be significantly less effective against Omicron, and that difference could impact our ability to estimate immunity against Omicron.

Early data seem to indicate that vaccine-induced antibodies may be less protective against Omicron, so vaccinated people are facing a greater risk of Omicron infection compared to previous variants. Booster may provide some protection, but a recent study from Denmark indicates that protection to be modest (only about 55% vaccine effectiveness) and of short duration (only about 30 days). On the other hand, some early studies from the UK have found that people infected with Omicron are less likely to be hospitalized compared to Delta. 

The significant differences between Omicron and previous variants makes the decision-making process more complex, and we encourage you to consult with your physician. However, Delta is still in the community and with new data being reported daily,  it is still important to “Know Your Number” so that you can think strategically about your immune status.

We will continue to monitor the situation and share our thoughts as the Omicron surge unfolds.

Is Quantimmune™ Right for Me?

Quantimmune empowers you to make informed health decisions with your doctor – click below to find out how!

The Science Behind Covid-19

What we know about the disease that has turned our world upside down.

Our Technology

Learn more about how Brevitest’s unique technology is changing the way we test.

Know. Now.

A Better Way to Test.

Have Any Questions?

FAQ's

If you have any additional questions, please email us here.

To assess the need and timing for a booster dose. Immune response to vaccine and/or infection varies among people. So, too, does the period of protection granted by the vaccine.. Since the antibody levels are generally thought to be a good marker of protection following most vaccinations, it can provide an objective measure to help make the decision about the optimal time to prescribe/take the booster shot.

To assess the immune response following COVID-19 infection or vaccination. Immune response to vaccination or infection tends to vary among people. It can be affected by age, genetic makeup, underlying disease, medications, etc. While vaccination confers protective immunity to most people, in some cases it does not, and it is vitally important to know in those cases so that appropriate precautions and lifestyle modifications can be made.

To make better decisions on rules for the workplace/public gatherings. In some institutions / public gatherings (like cruise ships or parks), vaccines are being mandated as a prerequisite for participation. However, for people who have already undergone COVID-19 infection, and are unwilling/unable to take the vaccine, a test for presence of significant levels of antibodies can help frame an alternative set of rules.

To encourage vaccination in a more rational and humane manner. Some people have resistance to vaccination because they believe they have either high ‘natural immunity’ or that they have acquired immunity through close contact with infected people. It can be beneficial to help them assess the truth of these beliefs through an accurate and easy test. It is hoped that objective evidence, and comparison to others in the same demographic, can help dispel misconceptions that can lead to uninformed decision-making.

To stratify risk for those with new COVID-19 infections. In patients with newly diagnosed COVID-19 infections who do not have prior immunity, antibody levels typically start to rise between 4-7 days after infection. However, for cases of infection in patients with prior vaccination/COVID-19 (‘breakthrough infection’), antibodies will likely be present at onset of infection. Since cases of breakthrough infection have much better prognosis than new infections, management of the disease can be objectively tailored.

Not quite. Immunity is a complex response involving many proteins (like antibodies and cytokines) and cells (immune cells like B and T lymphocytes). These components play different roles at different stages. However, antibody levels are a good marker of protection in many infections, and are regularly used to assess immune response for a number of other diseases. While research into the exact nature of COVID-19 is an ongoing, international effort, we do know that antibodies are generated as a result of infection and vaccination, and it is reasonable to assume that these antibodies seem to confer a material amount of immunity to most people.  

Brevitest is actively developing additional Quantimmune™ tests which will assess the cellular immunity against COVID-19. You can learn more about our future plans on our Product Road Map page.

It depends. Clinical testing at our research facility seem to indicate that in most cases antibodies against the primary variant bind to some extent to the variants. The exact degree of this binding seems to vary by person, as well as by variant. For example, Patient A’s antibodies, generated through vaccination, may bind with 40% efficacy to the Delta variant, but with 20% efficacy to the Beta (South African). The corresponding values for Patient B can be 60% and 15%. Brevitest is developing tests to compare antibody binding with different variants, so that test takers can get a more complete picture of their immune status. You can learn more about our future plans on our Product Road Map page.

The WHO has created a standard sample using pooled serum from donors. The concentration of IgG in this sample has been fixed at 1000 BAU/ml. The standard is available to clinical laboratories around the world. Brevitest has calibrated its readout using the standard, thereby enabling the result to be reported in BAU/ml.

For now, Brevitest is only accepting direct payment from clients for its test. However, it may be possible to get the cost reimbursed through your insurance – please contact them to explore this possibility.

The choice to monitor your immune response through assessment of antibody levels is a decision you should make in consultation with your physician or health care professional. Antibody levels change with time, as does immunity. Patients may choose to track this change through regular testing. Since these changes typically take place over weeks and months, they can choose an appropriate testing schedule.